

Medical Benefit Pharmacy Prior Approval List

Updated 11/07/2025

The following medications require Prior Approval. The medications are processed through the medical benefit. There may be additional medications that are handled through the Pharmacy Benefit. Please review the appropriate pharmacy benefit for complete Prior Approval list.

*Bevacizumab and bevacizumab biosimilars do not require prior approval for ophthalmic indications.

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Abecma	idecabtagene vicleucel	Q2055	AR 2024041	8/1/2021			
Actemra IV	tocilizumab IV	J3262	AR 2020022	4/1/2022			Preferred
Acthar	corticotropin	J0801	AR 2013048	12/1/2023			
Adakveo	crizanlizumab-tcma	J0791	AR 2020011	2/1/2020			
Adstiladrin	nadofaragene firadenovec-vncg	J9029	AR 2023020	5/24/2023			
Adzynma	ADAMTS13, recombinant-krhn	J7171	AR 2024020	6/19/2024			
Ahzantive	afilbercept-mrbb	Q5150	AR 2024066	3/12/2025		Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Cimerli (Q5128), Eylea HD (J0177) or Eylea (J0178) preferred]	Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Pavblu (Q5147) preferred]
Aldurazyme	laronidase	J1931	AR 2018025	9/1/2018			
Alymsys*	bevacizumab-maly	Q5126	AR 2017006 & AR 2023014	1/1/2024		Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]	Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]



Brand Name	Generic Name	HCPs	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Amtagvi	lifileucel	J9999	AR 2024019	7/1/2024			
Amvuttra	vutrisiran	J0225	AR 2022042	11/9/2022			
Anktiva	nogapendekin alfa inbakicept-pmln	J9028	AR 2024072	11/7/2024			
Aralast NP	alpha-1 proteinase inhibitor (human)	J0256	AR 2017001	9/1/2023			
Arcalyst	rilonacept	J2793	AR 2008031	10/1/2021			
Asparlas	calaspargase pegol	J9118	AR 2022019	8/1/2022			
Aucatzyl	obecabtagene autoleucel	Q2058	AR 2025004	2/26/2025			
Avastin*	bevacizumab	J9035	AR 2017006 & AR 2023014	1/1/2024		Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]	Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]
Avsola	infliximab-axxq	Q5121	AR 1998161	4/1/2022		Non-preferred [Inflectra (Q5103), Infliximab (J1745), Remicade (J1745) preferred]	Preferred
Avtozma	tocilizumab-anoh	Q5156	AR 2020022	6/25/2025			Non-preferred [Actemra (J3262), Tofidence (Q5133), and Tyenne (Q5135) preferred]
Avzivi*	bevacizumab-tnjn	C9399	AR 2017006 & AR 2023014	1/1/2026			Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]
Benlysta IV	belimumab IV	J0490	AR 2021033	10/1/2021			
Beovu	brovacizumab-dbl	J0179	AR 2024066	1/1/2025		Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Cimerli (Q5128), Eylea HD (J0177) or Eylea (J0178) preferred]	Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Pavblu (Q5147) preferred]
Beqvez	fidanacogene elaparovovec-dzkt	J1414	AR 2024067	9/1/2024			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Berinert	c1 esterase, inhibitor, human	J0597	AR 2013032	6/1/2018			
Bizengri	zenocutuzumab-zbco	J9382	AR 2025009	4/23/2025			
Bkemv	eculizumab-aeeb	Q5152	AR 2016013	4/23/2025		Non-preferred [Soliris (J1299) preferred]	Preferred
Blinicyto	blinatumomab	J9039	AR 2016009	10/11/2023			
Botox	onabotulinumtoxin a	J0585	AR 2018002 & AR 2000034	4/1/2022			
Breyanzi	lisocabtagene maraleucel	Q2054	AR 2024042	5/1/2021			
Brineura	cerliponase alfa	J0567	AR 2017022	4/1/2018			
Briumvi	ublituximab-siiy	J2329	AR 2023041	10/1/2023			
Cablivi	caplacizumab-yhdp	C9047	AR 2019006	8/1/2019			
Carvykti	ciltacabtagene autoleucel	Q2056	AR 2024040	6/1/2022			
Casgevvy	exagamglogene autotemcel	J3392	AR 2024013	5/29/2024			
Cerezyme	imiglucerase	J1786	AR 2023048	2/1/2024			
Cimerli	ranibizumab-eqrn	Q5128	AR 2024066	1/1/2026			Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Pavblu (Q5147) preferred]
Cimzia	certolizumab pego	J0717	AR 2024037	12/1/2024			
Cinqair	reslizumab	J2786	AR 2018008	6/1/2018			
Cinryze	c1 esterase, inhibitor, human	J0598	AR 2013032	6/1/2018			
Columvi	glofitamab-gxbm	J9286	AR 2023036	8/2/2023			
Cosela	trilaciclib	J1448	AR 2021046	4/23/2025			
Cosentyx IV	secukinumab IV	J3247	AR 2024016	5/29/2024			
Crysvita	burosumab-twza	J0584	AR 2018024	9/1/2018			
Danyelza	naxitamab-gqqgk	J9348	AR 2021017	2/28/2024			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Datroway	datopotamab deruxtecan-dlnk	J9011	AR 2025007	3/12/2025			
Daxxify	daxibotulinumtoxina-lanm	J0589	AR 2018002	2/28/2024			
Duopa	levodopa-carbidopa intestinal gel	J7340	AR 2018023	9/1/2018			
Dysport	abobotulinumtoxin a	J0586	AR 2018002	4/1/2022			
Elahere	mirvetuximab soravtansine-gynx	J9063	AR 2023019	5/17/2023			
Elaprase	idursulfase	J1743	AR 2018025	9/1/2018			
Elelyso	taliglucerase alfa	J3060	AR 2023048	2/1/2024			
Elevidys	delandistrogene moxeparvover-rold	J1413					
Elfabrio	pegunigalsidase alfa-iwxj	J2508	AR 2023013	8/2/2023			
Elrexio	elranatamab-bcmm	J1323	AR 2024006	3/6/2024			
Elzonris	tagrazofusp-erzs	J9269	AR 2020012	8/1/2019			
Encelto	revakinagene taroretcel-lwey	J3403	AR 2025021	7/30/2025			
Enjaymo	sutimlimab-jome	J1302	AR 2022024	7/1/2022			
Entyvio IV	vedolizumab IV	J3380	AR 2015011	4/1/2022			
Enzeevu	afilbercept-abzv	Q5149	AR 2024066	3/12/2025		Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Cimerli (Q5128), Eylea HD (J0177) or Eylea (J0178) preferred]	Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Pavblu (Q5147) preferred]
Epkinly	epcoritamab-bysp	J9321	AR 2023034	7/1/2023			
Epysqli	eculizumab-aagh	Q5151	AR 2016013	4/23/2025		Non-preferred [Soliris (J1299) preferred]	Preferred
Erzofri	paliperidone palmitate	J2428	AR 2016021	3/19/2024			
Evenity	romosozumab-aqqg	J3111	AR 2019009	8/1/2019			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Evkeeza	evinacumab-dgnb	J1305	AR 2021027	4/1/2021			
Eylea	aflibercept	J0178	AR 2024066	1/1/2026			Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Pavblu (Q5147) preferred]
Eylea HD	aflibercept	J0177	AR 2024066	1/1/2026			Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Pavblu (Q5147) preferred]
Fabrazyme	agalsidase beta	J0180	AR 2023013	4/13/2023			
Flolan	epoprostenol	J1325	AR 1998144	1/1/2025			
Fulphila	pegfilgrastim-jmdb	Q5108	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]	Preferred
Fyarro	sirolimus protein-bound particles	J9331	AR 2022022	9/1/2022			
Fynetra	pegfilgrastim-pbbk	Q5130	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]	Non-preferred [Neulasta (J2506), Neulasta Onpro (J2506) & Fulphila (Q5108) preferred]
Gamifant	emapalumab-lzsg	J9210	AR 2019013	11/1/2019			
Givlaari	givosiran	J0223	AR 2020009	4/1/2020			
Glassia	alpha-1 proteinase inhibitor human	J0257	AR 2017001	9/1/2023			
Grafapex	treosulfan	J0614	AR 2025003	3/19/2025			
Granix	tbo-filgrastim	J1447	AR 2021024	1/1/2024		Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]	Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]
Hemgenix	etranacogene dezaparvovec-drlb	J1411	AR 2023017	5/17/2023			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Herceptin	trastuzumab	J9355	AR 198158	1/1/2024		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]	Non-preferred [Kanjinti (Q5117), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Herceptin Hylecta	trastuzumab and hyaluronidase-oysk	J9356	AR 198158	1/1/2024		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]	Non-preferred [Kanjinti (Q5117), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Hercessi	trastuzumab-strf	Q5146	AR 198158	1/1/2025		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]	Non-preferred [Kanjinti (Q5117), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Herzuma	trastuzumab-pkrb	Q5113	AR 198158	1/1/2024		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]	Non-preferred [Kanjinti (Q5117), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Ilaris	canakinumab	J0638	AR 2020026	2/25/2021			
Ilumya	tildrakizumab-asnm	J3245	AR 2022048	4/1/2023			
Imdelltra	tarlatamab-dlle	J9026	AR 2024070	10/23/2024			
Imlygic	talimogene laherparepvec	J9325	AR 2025015	5/28/2025			
Imuldosa	ustekinumab-srlf	Q5098	AR 2021028	5/1/2025		Non-preferred [Stelara IV (J3358) & Stelara SC (J3357) preferred]	Non-preferred [Pyzchvia IV (Q9997), Pyzchvia SC (Q9996), Selarsdi (Q9998), Yesintek IV (Q5100) and Yesintek SC (Q9996)]
Inflectra	infliximab-dyyb	Q5103	AR 1998161	4/1/2022		Preferred	Preferred
Invega Sustenna	paliperidone palmitate	J2426	AR 2016021	4/1/2022			
Invega Trinza	paliperidone palmitate	J2427	AR 2016021	4/1/2022			
Istodax	romidepsin	J9319	AR 2021009	2/28/2024			
Ixifi	infliximab-qbtx	Q5109	AR 1998161	4/1/2022		Non-preferred [Inflectra (Q5103), Infliximab (J1745), Remicade (J1745) preferred]	Non-preferred [Inflectra (Q5103), Infliximab (J1745), Remicade (J1745) and Inflectra (Q5103) preferred]

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Jemperli	dostarlimab	J9272	AR 2022008	2/21/2024			
Jevtana	cabazitaxel	J9043	AR 2021013	3/6/2024			
Jobevne*	bevacizumab-nwgd	C9399	AR 2017006 & AR 2023014	1/1/2026			Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]
Kadcyla	ado-trastuzumab emtansine	J9354	AR 2013014	4/17/2024			
Kalbitor	ecallantide	J1290	AR 2013032	6/1/2018			
Kanjinti	trastuzumab-anns	Q5117	AR 198158	1/1/2024		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]	Preferred
Kanuma	sebelipase alfa	J2840	AR 2023035	11/1/2023			
Kebilidi	eladocagene exuparvovec	J3590	AR 2025006	3/12/2025			
Kimmtrak	tebentafusp-tebn	J9274	AR 2022023	6/15/2022			
Kisunla	donanemab-azbt	J0175	AR 2024077	12/18/2024			
Krystexxa	pegloticase	J2507	AR 2018027	12/1/2018			
Kymriah	tisagenlecleucel	Q2042	AR 1998109	7/1/2018			
Kyprolis	carfilzomib	J9047	AR 2021003	2/7/2024			
Lamzede	velmanase alfa-tycv	J0217	AR 2023018	5/1/2023			
Lanreotide (Cipla)	lanreotide	J1932	AR 2023038	4/1/2025			
Lemtrada	alemtuzumab	J0202	AR 2016015	4/1/2018			
Lenmeldy	atidarsagene autotemcel	J3391	AR 2024043	8/28/2024			
Leqvio	inclisiran	J1306	AR 2022016	7/15/2022			
Leukine	sargramostim	J2820	AR 2021024	1/1/2024		Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]	Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]
Lumizyme	alglucosidase alfa	J0221	AR 2020030	3/11/2021			
Lunsumio	mosunetuzumab-axgb	J9350	AR 2023024	5/15/2023			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Lutathera	lutetium Lu 177 Dotatate	A9513	AR 2018014	5/1/2018			
Luxturna	voretigene neparvovec-rzyl	J3398	AR 2018021	2/15/2023			
Lyfgenia	lovotibeglogene autotemcel	J3394	AR 2024014	5/29/2024			
Mepsevii	vestronidase alfa-vjbk	J3397	AR 2018025	9/1/2018			
Monjuvi	tafasitamab-cxix	J9349	AR 2021005	6/1/2023			
Mvasi*	bevacizumab-awwb	Q5107	AR 2017006 & AR 2023014	1/1/2024		Preferred	Preferred
Naglazyme	galsulfase	J1458	AR 2018025	9/1/2018			
Neulasta and Neulasta Onpro	pegfilgrastim	J2506	AR 2021024	1/1/2024		Preferred	Preferred
Neupogen	filgrastim	J1442	AR 2021024	1/1/2024		Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]	Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]
Nexvazyme	avalglucosidase alfa-ngpt	J0219	AR 2021041	12/1/2021			
Niktimvo	axatilimab	J9038	AR 2025008	4/16/2025			
Nivestym	filgrastim-aafi	Q5110	AR 2021024	1/1/2024		Preferred	Preferred
Nplate	romiplostim	J2802	AR 2008025	8/15/2023			
Nypozi	filgrastim-txid	Q5148	AR 2021024	1/1/2025		Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]	Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]
Nyvepria	pegfilgrastim-apgf	Q5122	AR 2021024	1/1/2024		Preferred	Non-preferred [Neulasta (J2506), Neulasta Onpro (J2506) & Fulphila (Q5108) preferred]

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Ocrevus	ocrelizumab	J2350	AR 2017021	4/15/2023			
Ocrevus Zunovo	ocrelizumab and hyaluronidase-ocsq	J2351	AR 2017021	1/22/2025			
Ogivri	trastuzumab-dkst	Q5114	AR 198158	1/1/2024		Preferred	Preferred
OmvoH	mirikizumab-mrkz	J2267	AR 2024011	4/24/2024			
Oncaspar	pegaspargase	J9266	AR 2022019	8/1/2022			
Onivyde	irinotecan liposomal	J9205	AR 2021018	3/1/2024			
Onpattro	patisiran	J0222	AR 2022042	2/1/2023			
Ontruzant	trastuzumab-dttb	Q5112	AR 198158	1/1/2024		Preferred	Preferred
Opdualag	nivolumab and relatlimab-rmbw	J9298	AR 2022038	10/1/2022			
Opuviz	aflibercept-yszy	Q5153	AR 2024066	3/12/2025		Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Cimerli (Q5128), Eylea HD (J0177) or Eylea (J0178) preferred]	Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Pavblu (Q5147) preferred]
Orencia	abatacept	J0129	AR 2006020	4/1/2022			
Otulfli IV and SC	ustekinumab-aaaz	Q9999	AR 2021028	3/5/2025		Non-preferred [Stelara IV (J3358) preferred]	Non-preferred [Pyzchvia IV (Q9997), Pyzchvia SC (Q9996), Selarsdi (Q9998), Yesintek IV (Q5100) and Yesintek SC (Q9996)]
Oxlumo	lumasiran	J0224	AR 2021032	9/15/2021			
Padcev	enfortumab vedotin-ejfv	J9177	AR 2021002	2/7/2024			
PiaSky	crovalimab-akkz	J1307	AR 2025001	1/15/2025			
Pluvicto	lutetium lu 177 vipivotide tetraxetan	A9607	AR 2022014	5/4/2022			
Pombiliti	cipaglucosidase alfa-atga	J1203	AR 2023051	12/19/2023			
Poteligeo	mogamulizumab-kpkc	J9204	AR 2022010	3/20/2024			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Prevymis IV	letermovir IV	J3490	AR 2018004	5/1/2024			
Prolastin	alpha-1 proteinase inhibitor human	J0256	AR 2017001	9/1/2023			
Pyzchiva IV	ustekinumab-ttwe	Q9997	AR 2021028	1/1/2025		Non-preferred [Stelara IV (J3358) preferred]	Preferred
Pyzchiva SC	ustekinumab-ttwe	Q9996	AR 2021028	1/1/2025		Non-preferred [Stelara SC (J3357) preferred]	Preferred
Qalsody	tofersen	J1304	AR 2023032	8/1/2023			
Radicava IV	edaravone IV	J1301	AR 2017026	12/1/2023			
Reblozyl	luspatercept-aamt	J0896	AR 2020006	3/1/2020			
Rebyota	fecal microbiota, live-jslm	J1440	AR 2023028	5/21/2023			
Releuko	filgrastim-ayow	Q5125	AR 2021024	1/1/2024		Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]	Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]
Relizorb	digestive enzyme cartridge	B4105	AR 2017029	8/1/2017			
Remicade and Unbranded Infliximab	infliximab	J1745	AR 1998161	4/1/2022		Preferred	Preferred
Remodulin	treprostinil IV	J3285	AR 1998144	1/1/2025			
Renflexis	infliximab-abda	Q5104	AR 1998161	4/1/2022		Non-preferred [Inflectra (Q5103), Infliximab (J1745), Remicade (J1745) preferred]	Non-preferred [Inflectra (Q5103), Infliximab (J1745), Remicade (J1745) and Inflectra (Q5103) preferred]
Rethymic	allogeneic processed thymus tissue-agdc	J3590	AR 2022034	8/22/2022			
Revatio	sildenafil (IV)	J3490	AR 1998144	4/1/2022			
Revcovi	elapegademase-lvlr	J3590	AR 2024082	4/1/2025			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Riabni	rituximab-arrx	Q5123	AR 2021034 & AR 2006016	4/1/2022		Non-preferred [Ruxience (Q5119) & Truxima (Q5115) preferred]	Preferred
Rituxan	rituximab	J9312	AR 2021034 & AR 2006016	4/1/2022		Non-preferred [Ruxience (Q5119) & Truxima (Q5115) preferred]	Non-preferred [Riabni (Q5123) & Truxima (Q5115) preferred]
Rituxan Hycela	rituximab and hyaluronidase	J9311	AR 2021034 & AR 2006016	4/1/2022		Non-preferred [Ruxience (Q5119) & Truxima (Q5115) preferred]	Non-preferred [Riabni (Q5123) & Truxima (Q5115) preferred]
Rivfloza	nedosiran	J3490	AR 2024017	6/5/2024			
Roctavian	valoctocogene roxaparvovec-rvox	J1412	AR 2023050	12/13/2023			
Rolvedon	eflapeggrastim-xnst	J1449	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]	Non-preferred [Neulasta (J2506), Neulasta Onpro (J2506) & Fulphila (Q5108) preferred]
Ruconest	c1 esterase, inhibitor, recombinant	J0596	AR 2013032	6/1/2018			
Ruxience	rituximab-pvvr	Q5119	AR 2021034 & AR 2006016	4/1/2022		Preferred	Non-preferred [Riabni (Q5123) & Truxima (Q5115) preferred]
Rybrevant	amivantamab-vmjw	J9061	AR 2021040	3/1/2024			
Rylaze	asparaginase erwinia chrysanthemi (recombinant)- rywn	J9021	AR 2022019	8/1/2022			
Ryoncil	remestemcel-L-rknd	J3402	AR 2025019	6/18/2025			
Ryplazim	plasminogen, human-tvmh	J2998	AR 2022002	1/12/2022			
Rystiggo	rozanolixizumab-nol	J9333	AR 2024004	2/14/2024			
Rytelo	imetelstat	J0870	AR 2024080	12/11/2024			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Ryzneuta	efbemalenograstim alfa-vuxw	J9361	AR 2021024	7/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]	Non-preferred [Neulasta (J2506), Neulasta Onpro (J2506) & Fulphila (Q5108) preferred]
Saphnelo	anifrolumab-fnia	J0491	AR 2022012	6/1/2022			
Selarsdi	ustekinumab-aekn	Q9998	AR 2021028	1/1/2025		Non-preferred [Stelara IV (J3358) & Stelara SC (J3357) preferred]	Preferred
Simponi Aria	golimumab	J1602	AR 2009015	4/1/2022			
Skyrizi IV	risankizumab-rzaa IV	J2327	AR 2022031	7/27/2022			
Skysona	elivaldogene autotemcel	J3590	AR 2023007	2/1/2023			
Soliris	eculizumab	J1299	AR 2016013	4/1/2018		Preferred	Preferred
Somatuline depot	lanreotide	J1930	AR 2023038	12/1/2023			
Spevigo	spesolimab-sbzo	J1747	AR 2023002	1/1/2023			
Spinraza	nusinersen	J2326	AR 2019011	4/1/2018			
Stelara IV	ustekinumab	J3358	AR 2021028	9/1/2021		Preferred	Non-preferred [Pyzchvia IV (Q9997), Pyzchvia SC (Q9996), Selarsdi (Q9998), Yesintek IV (Q5100) and Yesintek SC (Q9996)]
Stelara SC	ustekinumab	J3357	AR 2021028	9/1/2021		Preferred	Non-preferred [Pyzchvia IV (Q9997), Pyzchvia SC (Q9996), Selarsdi (Q9998), Yesintek IV (Q5100) and Yesintek SC (Q9996)]

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Steqeyma IV and SC	ustekinumab-stba	Q5099	AR 2021028	3/5/2025		Non-preferred [Stelara IV (J3358) preferred]	Non-preferred [Pyzchvia IV (Q9997), Pyzchvia SC (Q9996), Selarsdi (Q9998), Yesintek IV (Q5100) and Yesintek SC (Q9996)]
Stimufend	pegfilgrastim-fpgk	Q5127	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]	Non-preferred [Neulasta (J2506), Neulasta Onpro (J2506) & Fulphila (Q5108) preferred]
Susvimo	ranibizumab implant	J2779	AR 2025032	7/1/2022			
Talvey	talquetamab-tgvs	J3055	AR 2024007	3/6/2024			
Tecartus	brexucabtagene autoleucel	Q2053	AR 2024039	12/18/2020			
Tecelra	afamitresgene autoleucel	Q2057	AR 2024078	12/4/2024			
Tecvayli	teclistamab-cqyv	J9380	AR 2023015	4/19/2023			
Tepezza	teprotumumab-trbw	J3241	AR 2020004	3/23/2020			
Tivdak	tisotumab vedotin-tftv	J9273	AR 2022025	10/1/2022			
Tofidence	tocilizumab-bavi	Q5133	AR 2020022	5/15/2024			Preferred
Trazimera	trastuzumab-qyyp	Q5116	AR 198158	1/1/2024		Preferred	Non-preferred [Kanjinti (Q5117), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Tremfya IV	guselkumab IV	J1628	AR 2024071	10/23/2024			
Trodelvy	sacituzumab govitecan-hziy	J9317	AR 2020020	2/1/2023			
Truxima	rituximab-abbs	Q5115	AR 2021034 & AR 2006016	4/1/2022		Preferred	Preferred
Tyenne IV	tocilizumab-aaqg IV	Q5135	AR 2020022	7/1/2024			Preferred
Tyruko	natalizumab-sztn	Q5134	AR 2016018	12/1/2025			
Tysabri	natalizumab	J2323	AR 2016018	4/1/2022			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Tzield	teplizumab-mzwv	J9381	AR 2023012	4/19/2023			
Udenyca	pegfilgrastim-cbqv	Q5111	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]	Non-preferred [Neulasta (J2506), Neulasta Onpro (J2506) & Fulphila (Q5108) preferred]
Ultomiris	ravulizumab-cwyz	J1303	AR 2016013	2/1/2019			
Unloxcyt	cosibelimab ipdl	J9275	AR 2025017	6/4/2025			
Uplizna	inebilizumab-cdon	J1823	AR 2020016	7/1/2020			
Uptravi IV	selexipag IV	J3490	AR 1998144	1/1/2025			
Vegzelma*	bevacizumab-adcd	Q5129	AR 2017006 & AR 2023014	1/1/2024		Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]	Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]
Veletri	epoprostenol	J1325	AR 1998144	1/1/2025			
Veopoz	pozelimab-bbfg	J9376	AR 2024002	2/1/2024			
Viltepso	viltolarsen	J1427	AR 2016023	11/15/2025			
Vimizim	elosulfase alfa	J1322	AR 2018025	9/1/2018			
Vpriv	velaglucerase alfa	J3385	AR 2023048	2/1/2024			
Vyepti	eptinezumab-jjmr	J3032	AR 2020007	4/1/2022			
Vyjuvek	beremagene geperpavec-svdt	J3401	AR 2023047	12/13/2023			
Vyloy	zolbetuximab	J1326	AR 2025005	2/26/2025			
Vyvgart	efgartigimod alfa-fcab	J9332	AR 2022001	1/12/2022			
Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	J9334	AR 2024063	1/29/2025			
Wezlana IV	ustekinumab-auub	Q5138	AR 2021028	7/1/2024		Non-preferred [Stelara IV (J3358) preferred]	Non-preferred [Pyzchvia IV (Q9997), Pyzchvia SC (Q9996), Selarsdi (Q9998), Yesintek IV (Q5100) and Yesintek SC (Q9996)]

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Wezlana SC	ustekinumab-auub	Q5137	AR 2021028	7/1/2024		Non-preferred [Stelara SC (J3357) preferred]	Non-preferred [Pyzchvia IV (Q9997), Pyzchvia SC (Q9996), Selarsdi (Q9998), Yesintek IV (Q5100) and Yesintek SC (Q9996)]
Xenpozyme	olipudase alfa-rpcp	J0218	AR 2023008	2/1/2023			
Xeomin	incobotulinumtoxin a	J0588	AR 2018002	4/1/2022			
Xiaflex	clostrisidial collagenase	J0775	AR 2010013	8/1/2023			
Ycanth	cantharidin	J7354	AR 2024012	5/15/2024			
Yesafili	aflibercept-jbvf	Q5155	AR 2024066	1/1/2026			Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Pavblu (Q5147) preferred]
Yescarta	axicabtagene ciloleucel	Q2041	AR 2024038	7/1/2018			
Yesintek IV and SC	ustekinumab-kfce	Q5100	AR 2021028	3/5/2025		Non-preferred [Stelara IV (J3358) preferred]	Preferred
Zarxio	filgrastim-sndz	Q5101	AR 2021024	1/1/2024		Preferred	Preferred
Zemaira	alpha-1 proteinase inhibitor (human)	J0256	AR 2017001	9/1/2023			
Zepzelca	lurbinectedin	J9223	AR 2021001	7/1/2023			
Ziextenzo	pegfilgrastim-bmez	Q5120	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]	Non-preferred [Neulasta (J2506), Neulasta Onpro (J2506) & Fulphila (Q5108) preferred]
Ziihera	zanidatamab-hrii	J9276	AR 2025002	2/12/2025			
Zirabev*	bevacizumab-bvzr	Q5118	AR 2017006 & AR 2023014	1/1/2024		Preferred	Preferred
Zolgensma	onasemnogene abeparvovec-xioi	J3399	AR 2019011	8/1/2019			

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product	2026 Preferred Product
Zulresso	brexanolone	J1632	AR 2019012	8/15/2019	12/31/2025		
Zynlonta	loncastuximab tesirine-lpyl	J9359	AR 2022010	3/20/2024			
Zynteglo	betibeglogene autotemcel	J3393	AR 2022046	11/1/2022			